Persist AI, an AI and robotics-powered pharmaceutical formulation research company, announced on Wednesday that it has formed a strategic collaboration with pharmaceutical micronization specialists Microsize and Micromacinazione (Micmac).

Together, the three companies have built the world's first integrated platform capable of determining oral formulation strategy with milligrams of API, Persist AI said.

The 'Micromill' platform combines Micmac's SSM20 mini mill alongside Persist AI's AI-driven experimentation platform, enabling a complete, traceable formulation workflow using just milligrams of material. Persist AI said that, for the first time, formulation teams can make go/no-go decisions on micronization and bioavailability enhancement strategies at the earliest stages of development, when the cost of a course correction is a fraction of what it would be downstream.

The complete output spanning particle size distributions, solubility profiles, dissolution kinetics, stability indicators, and a full in-process characterization record is captured by Persist AI's self-learning agentic architecture, which builds deep knowledge with every experiment to reduce downstream formulation risk. The result is a formulation decision package that previously would have required extensive resource investment and API quantities unavailable in early development, Persist AI said.